Ken Ebihara Selected Research

Glucose (Dextrose)

1/2024	A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).
1/2023	Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
9/2020	Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
1/2020	Peripheral circadian rhythms in the liver and white adipose tissue of mice are attenuated by constant light and restored by time-restricted feeding.
1/2020	Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
1/2017	The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
10/2016	Fat Mass Reduction With Adipocyte Hypertrophy and Insulin Resistance in Heterozygous PPARγ Mutant Rats.
10/2014	Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
4/2012	Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
9/2011	Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken Ebihara Research Topics

Disease

18	Insulin Resistance 05/2024 - 01/2002
17	Obesity 10/2022 - 01/2002
6	Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy) 10/2022 - 05/2004
6	Body Weight (Weight, Body) 01/2020 - 12/2009
5	Lipoatrophic Diabetes Mellitus 05/2024 - 08/2004
4	Neoplasms (Cancer) 06/2023 - 02/2007
4	Fatty Liver 10/2022 - 11/2012
4	Insulinoma 05/2021 - 12/2005
4	Hypoglycemia (Reactive Hypoglycemia) 05/2021 - 09/2002
4	Hyperglycemia 09/2020 - 01/2005
4	Atherosclerosis 01/2020 - 01/2014
4	Lipodystrophy 06/2019 - 10/2012
3	Familial Partial Lipodystrophy (Dunnigan Syndrome) 01/2023 - 12/2009
3	Inflammation (Inflammations) 01/2020 - 05/2010
3	Autism Spectrum Disorder 05/2019 - 01/2017
2	Diabetes Mellitus 05/2024 - 01/2024
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2023 - 04/2021
2	Hyperlipidemias (Hyperlipidemia) 01/2022 - 01/2017
2	Weight Loss (Weight Reduction) 09/2020 - 04/2010
2	Type 2 Diabetes Mellitus (MODY) 12/2016 - 10/2014
2	Glucagonoma 01/2013 - 12/2005
2	Diabetes Complications 09/2011 - 02/2007
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2011 - 02/2009
2	Hypertrophy 04/2010 - 01/2005
2	Hyperphagia (Overeating) 07/2009 - 02/2009
2	Diabetic Nephropathies (Diabetic Nephropathy) 02/2009 - 01/2005
2	Hypertension (High Blood Pressure) 02/2007 - 01/2002
1	Ketosis 05/2024
1	Achlorhydria (Hypochlorhydria) 06/2023
1	Hypokalemia 06/2023
1	Vipoma (WDHA) 06/2023
1	Diarrhea 06/2023
1	Thyroiditis 05/2023
1	Graves Disease (Basedow Disease) 05/2023
1	Communicable Diseases (Infectious Diseases) 01/2023
1	COVID-19 01/2023
1	Severe Acute Respiratory Syndrome 01/2023
1	Leukemia 01/2023
1	Non-alcoholic Fatty Liver Disease 10/2022
1	Adenoma (Adenomas) 08/2022
1	Hyperaldosteronism (Conn Syndrome) 08/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Hypogonadism (Hypergonadotropic Hypogonadism) 04/2021
1	Kallmann Syndrome (Kallmann's Syndrome) 04/2021

Drug/Important Bio-Agent (IBA)

20	LeptinIBA 10/2022 - 01/2002
16	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2002
14	Insulin (Novolin)FDA Link 01/2024 - 01/2002
6	Triglycerides (Triacylglycerol)IBA 01/2022 - 02/2007
4	LipidsIBA 01/2020 - 08/2005
4	Hormones (Hormone)IBA 04/2012 - 01/2005
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2023 - 10/2016
3	Messenger RNA (mRNA)IBA 01/2023 - 12/2005
3	CholesterolIBA 01/2020 - 11/2018
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2017 - 12/2005
3	AMP-Activated Protein KinasesIBA 11/2012 - 02/2009
3	MelanocortinsIBA 07/2009 - 01/2002
2	empagliflozinIBA 05/2024 - 01/2024
2	SodiumIBA 01/2024 - 09/2020
2	C-PeptideIBA 01/2023 - 02/2007
2	Pioglitazone (Actos)FDA Link 01/2023 - 12/2009
2	LipopolysaccharidesIBA 01/2023 - 11/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2023 - 11/2015
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 09/2013
2	Therapeutic UsesIBA 10/2022 - 11/2012
2	ThiazolidinedionesIBA 10/2022 - 12/2009
2	CollagenIBA 01/2022 - 11/2015
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 04/2021
2	Nonsense Codon (Nonsense Mutation)IBA 04/2021 - 05/2004
2	Hypoglycemic Agents (Hypoglycemics)IBA 09/2020 - 04/2012
2	Insulin ReceptorIBA 09/2020 - 06/2019
2	ipragliflozinIBA 09/2020 - 12/2016
2	EnzymesIBA 01/2020 - 04/2010
2	kamisyoyo sanIBA 05/2019 - 01/2019
2	Pregnanolone (Allopregnanolone)IBA 01/2019 - 01/2017
2	CytokinesIBA 11/2018 - 11/2015
2	Streptozocin (Streptozotocin)FDA Link 10/2014 - 02/2009
2	Islet Amyloid PolypeptideIBA 04/2012 - 01/2011
2	AngiotensinogenIBA 09/2010 - 04/2010
2	GlucocorticoidsIBA 05/2010 - 05/2009
2	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 02/2009 - 01/2002
1	KetonesIBA 05/2024
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2024
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 06/2023
1	AntibodiesIBA 05/2023
1	27-hydroxycholesterolIBA 01/2023
1	OxysterolsIBA 01/2023
1	7-ketocholesterolIBA 01/2023
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023
1	cholesterol 25-hydroxylaseIBA 01/2023
1	Interferon-gamma (Interferon, gamma)IBA 01/2023
1	25-hydroxycholesterolIBA 01/2023
1	Rosiglitazone (Avandia)FDA Link 10/2022
1	AldosteroneIBA 08/2022
1	Sterol Regulatory Element Binding Protein 1IBA 01/2022
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2022
1	lanreotide (Somatuline)FDA Link 05/2021
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 05/2021
1	Octreotide (Sandostatin)FDA LinkGeneric 05/2021

Therapy/Procedure

8	Therapeutics 01/2019 - 08/2004
2	Gastrectomy 11/2015 - 01/2014